Technology Vision Group (TVG) announces an exciting and extensive programme for its European partnering conference, BioPartnering Europe (BPE). BPE, which takes place from 12th–14th October, 2008 at the Queen Elizabeth Conference Centre in London, UK, is the premier biotechnology partnering and networking event in Europe. This years conference aims to not only maximise attendees opportunities to increase their profile within the biotechnology sector, but will also examine key topics facing the industry.
Unlimited Partnering Potential with Biopartnering.com
biopartnering.com is a unique and powerful internet platform developed by TVG to enhance conference participation before, during and after BPE. Conference delegates began arranging meetings through biopartnering.com on 2nd June, 2008. biopartnering.com facilitates automated meeting scheduling and includes powerful search tools to help users identify key targets. biopartnering.com also includes time management tools that allow attendees to make the most of their time at the conference and ensure that they capitalize on all the opportunities afforded at BPN.
The biopartnering meeting scheduler is now open!
To find out more about BioPartnering Europe please visit www.techvision.com/bpe
Conference Highlights
BioPartnering Leadership Sessions
One of the most popular features of BPE are the BioPartnering Leadership Sessions, where some of the most important issues influencing the growth of the life science industry are debated by a group of key decision makers. Sessions include:
- Artistic Masterpieces - Industry experts such as Dr. Genghis Lloyd–Harris, Abingworth and Dr. Charles Wilson from Novartis, will discuss some of the more creative and transformational deals in the sector.
- Deal or No Deal - A highly experienced panel including Karl Keegan, Canaccord Adams and Daniel Pavin, Taylor Wessing, will review and discuss the market expectations for deal terms in the sector currently.
- BIOFORECASTER - An expert panel of sector specialists and biotechnology analysts return to review the sector and give their predictions for the coming six months.
Register online at: www.techvision.com/bpe/registration/
This year´s program will also include Sponsor Workshops and Company Presentations that aim to highlight key issues and themes through topical debate, as well as providing the perfect platform for biotech companies seeking potential partners and business opportunities to raise their profile.
This year´s conference is featuring a completely new presenting format, designed so that more companies can take advantage of the excellent presenting options and company promotional tools. There is still a limited amount of presenting opportunities available. Find out which format is right for you in the descriptions below.
To apply to present, please contact Lila Taylor at ltaylor@techvision.com or visit http://www.techvision.com/bpe/apply/
Dedicated Meeting Booth
The option to purchase a dedicated meeting booth this year allows attendees from any industry to reserve a meeting space for either one or two days. Companies can invite attendees to meet at their booth via biopartnering.com.
Podium Presentations
180 life science companies will offer 13–minute podium presentations over the course of the two days. Presenters will be able to introduce their company, showcase key technologies and highlight partnering goals. Benefits include two conference tickets as well as access to the VIP presenter lounge.
Open House Presentation & Dedicated Meeting Booth
In this format, life science companies enjoy optimal benefits with access to a meeting booth for an entire day. The booth will feature a dedicated 2–hour time period to showcase their company and also have private meeting space where they can continue their discussions. The format allows for two hours use of the booth as an Open House interactive / multi–media space and then five hours use of the booth as a meeting room with the opportunity to schedule meetings directly through biopartnering.com. This option includes two conference tickets.
About Technology Vision Group
Technology Vision Group LLC (TVG) is one of the leading business development organizations serving the international life sciences industry. Since 1992, TVG has been developing innovative methods to help life science and associated technology companies attract partners and investors, acquire new products and technologies, and achieve a variety of other strategic business development goals.
Confirmed Presenting Companies:
4–Antibody AG, Ablynx NV, ACE BioSciences, Aerie Pharmaceuticals, Inc, AFFITECH AS, Agile Therapeutics, Inc., AlgoNomics, Alios BioPharma, Allergy Therapeutics plc, Alligator Bioscience AB, Allozyne, Ambit Biosciences, AM–Pharma, Apthera, Inc., Aquinox Pharmaceuticals Inc., Arana Therapeutics Ltd, Archimedes Pharma Ltd, Ardea Biosciences, Argos Therapeutics, Inc, ARIUS Research Inc., Asphelia Pharmaceuticals, Avecia Biologics, AviGenics Inc., Balter Medical, BaroFold, Inc, Baxter Asia Pacific, Biocompatibles Ltd., Biocontrol Ltd, BioFocus DPI Ltd., Biolex Therapeutics, BioSeek, Inc., BiPar Sciences, BN ImmunoTherapeutics, BTG International Ltd., Calabar AB, Celleron Therapeutics, Cellzome, Cequent Pharmaceuticals, Inc., Ceregene Inc., Cerenis Therapeutics, Circassia, Clinical Data, Inc., CNSBio Pty Ltd, CoLucid Pharmaceuticals Inc., CoMentis, Inc., Concert Pharmaceuticals, Inc., Critical Pharmaceuticals Ltd, Curis, Inc, Cyclacel, Cytokinetics, Inc., DBV Technologies, Debiopharm S.A., deCODE chemistry & biostructures, Delcath Systems, Inc., Delphi Genetics, DIREVO Biotech AG, e2v biosensors ltd, EcoBiotics Limited, Egalet A/S, Emergent BioSolutions, Endoceutics, EntreMed, Inc., Equinox Pharma Limited, Essentialis, Inc., Eurand International S.p.A., Evotec, Flamel Technologies S.A., f–star Biotechnology, Ganymed Pharmaceuticals AG, Genera Biosystems Limited, Glytech, Haemostatix Ltd, Halozyme Therapeutics, Inc., Health Protection Agency, Heptares Therapeutics, Hypo–Safe A/S, ImmunoVaccine Technologies Inc., Indevus Pharmaceuticals, Inc., Innate Pharma, InNexus Biotechnology Inc., Intas Biopharmaceuticals Ltd., Interleukin Genetics, Inc., Intermune Inc., Ipsat Therapies Oy, Isconova AB, Jazz Pharmaceuticals, KAI Pharmaceuticals Inc., Lamellar Biomedical Limited, Lectus Therapeutics Limited, Lentigen, LifeCycle Pharma, MBC Pharma, Inc, Medelis, MedPharm Ltd, Micromet AG, Moberg Derma AB, Modern Biosciences plc, Molecular Profiles Ltd, MolMed S.p.A., MorphoSys AG, Nektar Therapeutics, Neogenix Oncology Corporation, Neurobiological Technologies Inc., Neurocrine Biosciences, Inc., Neurotech Pharmaceutical Co., Ltd., NextPharma GmbH, Norgine, Novacta Biosystems Limited, Novosom AG, Novozymes A/S, NsGene A/S, Numerate Inc., NuPathe Inc., Office of Biomedical Advanced Research and Development Authority (BARDA), Olink Bioscience, Oncolytics Biotech Inc., Panacos Pharmaceuticals, Inc, PharmaNova Inc., PlexPress, PolyMedix Inc., PolyTherics, Presidio Pharmaceuticals, Probiodrug AG, ProCell Therapeutics, Inc., Pronota, Propanc Pty Ltd, Prosonix Ltd, Protalix Biotherapeutics Inc., Q Chip Ltd, Receptor BioLogix, REVOTAR Biopharmaceuticals AG, SciClone Pharmaceuticals, Inc., Selvita sp. z o.o., SemBioSys Genetics Inc., Sequoia Sciences, Inc., Serodus AS, Serometrix LLC, Shire Pharmaceuticals Group Ltd., Sidec AB, Silence Therapeutics AG, Simcere Pharmaceutical Incorporation, Spectrum Pharmaceuticals, Inc, Summit plc, SuperGen Inc., Symphogen A/S, Synosia Therapeutics, Syntaxin Ltd, Tetraphase Pharmaceuticals, Therosteon, TheRyte Ltd., TopoTarget A/S, Transcept Pharmaceuticals, Transdel Pharmaceuticals, Inc., Tranzyme, Inc., TriStar Technology Group, LLC, TROPHOS, UCB Group, University of Nottingham, Vakzine Projekt Management GmbH (VPM), ValiBIO SA, Verva Pharmaceuticals, Ltd., Vivostat, VLST Corp, Vyteris, Xenome Ltd, XOMA Ltd., YM BioSciences Inc.
Sponsors
AstraZeneca, Deloitte, Takeda Pharmaceuticals, Taylor Wessing, Cooley, Ferghana Partners, Goodwin Procter, Abbott, Amgen, Bristol–Myers Squibb, Glaxo–Smith Kline, International Business Wales, Johnson & Johnson, Merck, Novartis, Pfizer, Procter & Gamble Pharmaceuticals, Roche, UKTI, Farris, Vaughan, Wills and Murphy, ImmuPharma, and Genzyme
Conference Supporters
BioCentury, BioPharm International, BioSquare, Biotech 360, BioWorld, Business Wire, Citigate Dewe Rogerson, European Biotechnology News, Nature Publishing Group
GBP Supporters
ap bio, Bay Bio, BIA, Bio now, ERBI, European Federation of Biotechnology, LifeSciences, British Columbia, UBI France
